Thursday, April 22, 2010, noon to 1:00pm
Lunch available at 11:45
ATLAS 229, CU-Boulder>
This seminar hosted by TTO and the Colorado Institute for Molecular Biotechnology (CIMB) will offer strategies and perspectives on commercializing early-stage biomedical technologies, with a particular focus on intellectual property protection.
- Focused on drug targets, drug screens/selection platforms, early-stage drugs, and other therapeutic platform technologies
- What patent strategies are available for these technologies?
- How can you maximize the commercial viability and value of these technologies?
- Will also include information on resources available to CU researchers through the Colorado Initiative in Molecular Biotechnology (CIMB).
Tad H. Koch is a Professor of Chemistry & Biochemistry. Professor Koch has assembled a collection of issued and pending patents for his invention of anthracycline-based, anti-tumor drug candidates.
Robert D. Traver is a patent attorney with Sheridan Ross P.C., and has experience in the general areas of chemistry, pharmaceuticals and biotechnology. Rob is the attorney prosecuting Professor Koch’s portfolio of patent applications.
This event is free and open to CU faculty from all campuses. Lunch will be provided – please RSVP by via email or at 303-735-6645.